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tasis: immunoglobulins, aspergillus antibodies, 
antinuclear antibody (ANA) and antineutrophil 
cy top lasmic  an t ibody  (ANCA)  ta rge t ing 
myeloperoxidase (MPO) and proteinase 3 (Pr3), 
native anti-DNA antibodies, extractable nuclear 
antigen (ENA) autoimmunity profile, procalcitonin, 
C-reactive protein (CRP) and blood count, all of 
them were normal. The functional study using 
spirometry and plethysmography showed a very 
severe obstructive disorder (forced expiratory 
volume in one second [FEV1] of 38%) with a 
decrease in forced vital capacity (FVC) of 44% 
without response to bronchodilators associated 
with a severe increase in residual volume (RV: 
160%) and functional residual capacity (FRC: 
180%) with normal total lung capacity (TLC: 118%) 
and severe decrease in the diffusion capacity of 
carbonmonoxide (DLCO: 27%). In the 6-minute 
walk test the patient walked 400 meters (adequate 
for her age) with a resting saturation of 94% and a 
minimum saturation during the test of 88%.
With respect to specific examinations for the study 
of CF, 4 chloride sweat tests were carried out using 
the pilocarpine method. All the results were within 
the indeterminate range (30 - 60 mmol / L): 41, 37, 
44 and 42 mmol / L, respectively, which is unusual in 
infectious bronchiectasis. Although more useful in 
neonates and children, a serum immunoreactive 
trypsin test was also performed: 764 ng / mL (very 
high). In May, 2016 a genetic study for CF carried 
out by massive sequencing and found the presence 
of the c.3274T> C mutation (p.Tyr1092His) in one of 
the alleles of the CFTR gene; this first study 
evaluated 24 mutations of this gene. A second 
genetic study conducted in 2019 evaluated 36 
genes related to CF, immunodeficiencies, and 
primary ciliary dyskinesia found the same c.3274T> 
Figure 1. Comparative chest X-Ray: 2014 (upper left corner) and 2019 (upper right corner). Computed 
tomography of the chest (2019): bilateral cystic bronchiectasis that was later located predominantly 
in the upper and lower left lobe and the lower right lobe
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Abstract
CF is an autosomal recessive disease, requiring mutations to be present in both 
alleles in the CF transmembrane conductance regulatory gene (CFTR). The 
c.3274T> C (p.Tyr1092His) mutation is not registered in the “CFTR2 project” 
database, but it is registered in The Human Gene Mutation Database. Neither are 
the two DNAAF4 c.1177C> T (p.Leu393Phe) and DNAAF5 c.1195G> A 
(p.Glu399Lys) mutations found in the "CFTR Project”, and their clinical 
consequences are currently uncertain. Here, we report the case of a Peruvian 
woman presenting this mutation, bronchiectasis and loss of lung function and 
provide a review of the literature.
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Resumen
La FQ es una enfermedad autosómica recesiva que requiere la presencia de 
mutaciones en ambos alelos del gen regulador de la conductancia 
transmembrana de la FQ (CFTR). La mutación c.3274T> C (p.Tyr1092His) no 
está registrada en la base de datos del “proyecto CFTR2”, pero está registrada en 
la base de datos de mutaciones de genes humanos. Ademas otras dos 
mutaciones DNAAF4 c.1177C> T (p.Leu393Phe) y DNAAF5 c.1195G> A 
(p.Glu399Lys) encontradas en el "Proyecto CFTR", son actualmente inciertas en 
sus consecuencias clínicas. A continuación, presentamos el caso de una mujer 
peruana que presenta esta mutación, bronquiectasias y pérdida de función 
pulmonar y se proporciona una revisión de la literatura.
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Introduction
In 2019, about 80,000 patients were registered as 
having cystic fibrosis (CF) in the United States and 
Europe (1). The clinical diagnosis of CF during 
adulthood is a difficult because: 1) the vast majority 
of patients do not undergo neonatal screening, 
especially in Peru; 2) systemic manifestations are 
usually infrequent; and 3) bronchiectasis-like lung 
lesions and chronic respiratory symptoms due to 
functional compromise are usually considered as 
pulmonary tuberculosis or as secondary lesions (2). 
The latter is very frequent in countries such as Peru 
where the prevalence of tuberculosis is high. Adults 
with CF may have a residual function of the gene 
involved in CF, and thus, the sweat chloride test with 
pilocarpine (gold standard test) is usually not 
positive, leading to indeterminate results (3,4), 
making molecular biology studies necessary to 
achieve a definitive diagnosis (1,5).
CF is an autosomal recessive disease, requiring 
mutations to be present in both alleles in the CF 
transmembrane conductance regulatory gene 
(CFTR). More than 2,000 mutations have been 
described in this gene, but only 412 mutations have 
been fully characterized (6). The different variations 
in mutations can be classified as: a) CF-causing 
variants, b) pathogenic variants of variable clinical 
significance, c) non-disease-causing variants, and 
d) variants of uncertain significance (3,4). The most 
frequent mutation worldwide is delta F508, although 
its presence varies considerably between races and 
regions. Here, we report the case of a peruvian 
woman who gave her consent presenting this 
mutation and provide a review of the literature.
Case Report
The patient was a 44-year-old woman, a native of 
the Department of Huancavelica (3,676 meters 
above sea level) in the Peruvian highlands, presen-
ting nearly 40 years of respiratory symptoms 
including: cough, phlegm, and dyspnea. At the age 
of 30, she was diagnosed with a pulmonary sequela 
due to untreated tuberculosis after several previous 
radiographs showed lung lesions of the bronchiec-
tasis type. For several years, only sputum samples 
were requested in search of M. tuberculosis, all of 
which were negative. The general examinations did 
not show striking alterations. Chest tomography 
showed initially diffuse bilateral cystic bronchiec-
tasis that was later located predominantly in the 
upper and lower left lobe and the lower right lobe 
(Figure 1). The paranasal sinuses showed no 
alterations. No fungal microorganism was isolated.
On referral to our unit, and after obtaining informed 
consent from the patient, the following analyses 
were made to determine the cause of bronchiec-
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tasis: immunoglobulins, aspergillus antibodies, 
antinuclear antibody (ANA) and antineutrophil 
cy top lasmic  an t ibody  (ANCA)  ta rge t ing 
myeloperoxidase (MPO) and proteinase 3 (Pr3), 
native anti-DNA antibodies, extractable nuclear 
antigen (ENA) autoimmunity profile, procalcitonin, 
C-reactive protein (CRP) and blood count, all of 
them were normal. The functional study using 
spirometry and plethysmography showed a very 
severe obstructive disorder (forced expiratory 
volume in one second [FEV1] of 38%) with a 
decrease in forced vital capacity (FVC) of 44% 
without response to bronchodilators associated 
with a severe increase in residual volume (RV: 
160%) and functional residual capacity (FRC: 
180%) with normal total lung capacity (TLC: 118%) 
and severe decrease in the diffusion capacity of 
carbonmonoxide (DLCO: 27%). In the 6-minute 
walk test the patient walked 400 meters (adequate 
for her age) with a resting saturation of 94% and a 
minimum saturation during the test of 88%.
With respect to specific examinations for the study 
of CF, 4 chloride sweat tests were carried out using 
the pilocarpine method. All the results were within 
the indeterminate range (30 - 60 mmol / L): 41, 37, 
44 and 42 mmol / L, respectively, which is unusual in 
infectious bronchiectasis. Although more useful in 
neonates and children, a serum immunoreactive 
trypsin test was also performed: 764 ng / mL (very 
high). In May, 2016 a genetic study for CF carried 
out by massive sequencing and found the presence 
of the c.3274T> C mutation (p.Tyr1092His) in one of 
the alleles of the CFTR gene; this first study 
evaluated 24 mutations of this gene. A second 
genetic study conducted in 2019 evaluated 36 
genes related to CF, immunodeficiencies, and 
primary ciliary dyskinesia found the same c.3274T> 
Figure 1. Comparative chest X-Ray: 2014 (upper left corner) and 2019 (upper right corner). Computed 
tomography of the chest (2019): bilateral cystic bronchiectasis that was later located predominantly 
in the upper and lower left lobe and the lower right lobe
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Introduction
In 2019, about 80,000 patients were registered as 
having cystic fibrosis (CF) in the United States and 
Europe (1). The clinical diagnosis of CF during 
adulthood is a difficult because: 1) the vast majority 
of patients do not undergo neonatal screening, 
especially in Peru; 2) systemic manifestations are 
usually infrequent; and 3) bronchiectasis-like lung 
lesions and chronic respiratory symptoms due to 
functional compromise are usually considered as 
pulmonary tuberculosis or as secondary lesions (2). 
The latter is very frequent in countries such as Peru 
where the prevalence of tuberculosis is high. Adults 
with CF may have a residual function of the gene 
involved in CF, and thus, the sweat chloride test with 
pilocarpine (gold standard test) is usually not 
positive, leading to indeterminate results (3,4), 
making molecular biology studies necessary to 
achieve a definitive diagnosis (1,5).
CF is an autosomal recessive disease, requiring 
mutations to be present in both alleles in the CF 
transmembrane conductance regulatory gene 
(CFTR). More than 2,000 mutations have been 
described in this gene, but only 412 mutations have 
been fully characterized (6). The different variations 
in mutations can be classified as: a) CF-causing 
variants, b) pathogenic variants of variable clinical 
significance, c) non-disease-causing variants, and 
d) variants of uncertain significance (3,4). The most 
frequent mutation worldwide is delta F508, although 
its presence varies considerably between races and 
regions. Here, we report the case of a peruvian 
woman who gave her consent presenting this 
mutation and provide a review of the literature.
Case Report
The patient was a 44-year-old woman, a native of 
the Department of Huancavelica (3,676 meters 
above sea level) in the Peruvian highlands, presen-
ting nearly 40 years of respiratory symptoms 
including: cough, phlegm, and dyspnea. At the age 
of 30, she was diagnosed with a pulmonary sequela 
due to untreated tuberculosis after several previous 
radiographs showed lung lesions of the bronchiec-
tasis type. For several years, only sputum samples 
were requested in search of M. tuberculosis, all of 
which were negative. The general examinations did 
not show striking alterations. Chest tomography 
showed initially diffuse bilateral cystic bronchiec-
tasis that was later located predominantly in the 
upper and lower left lobe and the lower right lobe 
(Figure 1). The paranasal sinuses showed no 
alterations. No fungal microorganism was isolated.
On referral to our unit, and after obtaining informed 
consent from the patient, the following analyses 
were made to determine the cause of bronchiec-
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C mutation (p.Tyr1092His) in one of the alleles of 
the CFTR gene. Additionally, the presence of 
heterozygosity of the DNAAF4 c.1177C> T 
(p.Leu393Phe)  and DNAAF5 c.1195G> A 
(p.Glu399Lys) was found; the first mutation is not 
present in the database (https://gnomad.broadins 
titute.org/) and the second has a frequency in the 
population of 0.00003605%, and neither mutation 
has known clinical correlation.
A blood count was performed on March 5, 2020, 
showing a leukocyte count of 14,900 / mm3 and 
CRP level of 53.6 mg / L. Two blood cultures was 
negative. The growth of Pseudomonas aeruginosa 
in sputum culture was found to be sensitive to 
piperacill in / tazobactam, third and fourth 
generation cephalosporins, carbapenems, 
aztreonam and fluoroquinolones with intermediate 
sensitivity to colistin, and therefore, antibiotic 
treatment was initiated with ceftazidime 2 g every 8 
hours intravenous plus amikacin 750 mg every 24 
hours also intravenous and nebulized colistin every 
12 hours for 28 days. Azithromycin at 500 mg was 
also started 3 times per week. Sputum cultures 
taken on March 18 and 28, 2020 showed no 
bacterial growth and the patient remains stable.
Discussion
There are many more mutations or variants that can 
affect the course, the clinical manifestations, and 
the severity of the disease (7-10). The diagnosis of 
CF with molecular biology techniques is based on 
the recommendations of the “Cystic Fibrosis 
Foundation” that uses the “CFTR2 project 
database” (11-13). Little is known about the 
mutation in exon 20 of the CFTR gene located on 
chromosome 7q31.2 known as c.3274T> C 
(p.Tyr1092His or y1092h) and identified in the 
HGMD (The Human Gene Mutation Database) with 
the code Cm972958.
According to ClinVar (www.ncbi.nlm.nih.gov/ 
clinvar/variation/495930/), this mutation is 
classified as a variant of uncertain significance.
The c.3274T> C (p.Tyr1092His) mutation is not 
registered in the “CFTR2 project” database, but it is 
registered in the HGMD database. Neither are the 
two DNAAF4 c.1177C> T (p.Leu393Phe) and 
DNAAF5 c.1195G> A (p.Glu399Lys) mutations 
found in the "CFTR Project”, and their clinical 
consequences are currently uncertain. The 
c.3274T> C (p.Tyr1092His) mutation has been 
found on a Caucasian chromosome in the United 
States. This mutation was also found in a 9-year-old 
patient diagnosed with asthma in which 2 chloride 
sweat tests were also undetermined: 58 and 52 
mmol / L respectively, and sputum cultures were 
negative for Staphylococci and Pseudomonas. In 
Europe, the c.3274T> C mutation (p.Tyr1092His) 
was found in only one out of a total of 62 patients 
with CF evaluated in Italy and was reported as 
accompanying a CF-causing mutation or variant 
(14,15).
We believe that the c.3274T> C (p.Tyr1092His) 
mutation, together with the DNAAF4 c.1177C> T 
(p.Leu393Phe)  and DNAAF5 c.1195G>  A 
(p.Glu399Lys) mutations, are  responsible for the 
clinical and functional manifestations and the 
progressive pulmonary lesions observed in the 
tomography of our patient. We also believe that they 
are the cause of the alterations of the biomarkers in 
chloride sweat tests and serum immuno reactive 
trypsin. Globally, the c.3274T> C (p.Tyr1092His) 
mutations has only been  previously reported in 3 
patients: two with CF and one with asthma. 
Although the present case did not involve CF, the 
genetic background of the patient is likely to underly 
the cause of her disease.  The findings of this case 
suggest the need to study the presence of possible 
mutat ions in  cases o f  suspected CF or 
bronchiectasis of unknown cause.
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C mutation (p.Tyr1092His) in one of the alleles of 
the CFTR gene. Additionally, the presence of 
heterozygosity of the DNAAF4 c.1177C> T 
(p.Leu393Phe)  and DNAAF5 c.1195G> A 
(p.Glu399Lys) was found; the first mutation is not 
present in the database (https://gnomad.broadins 
titute.org/) and the second has a frequency in the 
population of 0.00003605%, and neither mutation 
has known clinical correlation.
A blood count was performed on March 5, 2020, 
showing a leukocyte count of 14,900 / mm3 and 
CRP level of 53.6 mg / L. Two blood cultures was 
negative. The growth of Pseudomonas aeruginosa 
in sputum culture was found to be sensitive to 
piperacill in / tazobactam, third and fourth 
generation cephalosporins, carbapenems, 
aztreonam and fluoroquinolones with intermediate 
sensitivity to colistin, and therefore, antibiotic 
treatment was initiated with ceftazidime 2 g every 8 
hours intravenous plus amikacin 750 mg every 24 
hours also intravenous and nebulized colistin every 
12 hours for 28 days. Azithromycin at 500 mg was 
also started 3 times per week. Sputum cultures 
taken on March 18 and 28, 2020 showed no 
bacterial growth and the patient remains stable.
Discussion
There are many more mutations or variants that can 
affect the course, the clinical manifestations, and 
the severity of the disease (7-10). The diagnosis of 
CF with molecular biology techniques is based on 
the recommendations of the “Cystic Fibrosis 
Foundation” that uses the “CFTR2 project 
database” (11-13). Little is known about the 
mutation in exon 20 of the CFTR gene located on 
chromosome 7q31.2 known as c.3274T> C 
(p.Tyr1092His or y1092h) and identified in the 
HGMD (The Human Gene Mutation Database) with 
the code Cm972958.
According to ClinVar (www.ncbi.nlm.nih.gov/ 
clinvar/variation/495930/), this mutation is 
classified as a variant of uncertain significance.
The c.3274T> C (p.Tyr1092His) mutation is not 
registered in the “CFTR2 project” database, but it is 
registered in the HGMD database. Neither are the 
two DNAAF4 c.1177C> T (p.Leu393Phe) and 
DNAAF5 c.1195G> A (p.Glu399Lys) mutations 
found in the "CFTR Project”, and their clinical 
consequences are currently uncertain. The 
c.3274T> C (p.Tyr1092His) mutation has been 
found on a Caucasian chromosome in the United 
States. This mutation was also found in a 9-year-old 
patient diagnosed with asthma in which 2 chloride 
sweat tests were also undetermined: 58 and 52 
mmol / L respectively, and sputum cultures were 
negative for Staphylococci and Pseudomonas. In 
Europe, the c.3274T> C mutation (p.Tyr1092His) 
was found in only one out of a total of 62 patients 
with CF evaluated in Italy and was reported as 
accompanying a CF-causing mutation or variant 
(14,15).
We believe that the c.3274T> C (p.Tyr1092His) 
mutation, together with the DNAAF4 c.1177C> T 
(p.Leu393Phe)  and DNAAF5 c.1195G>  A 
(p.Glu399Lys) mutations, are  responsible for the 
clinical and functional manifestations and the 
progressive pulmonary lesions observed in the 
tomography of our patient. We also believe that they 
are the cause of the alterations of the biomarkers in 
chloride sweat tests and serum immuno reactive 
trypsin. Globally, the c.3274T> C (p.Tyr1092His) 
mutations has only been  previously reported in 3 
patients: two with CF and one with asthma. 
Although the present case did not involve CF, the 
genetic background of the patient is likely to underly 
the cause of her disease.  The findings of this case 
suggest the need to study the presence of possible 
mutat ions in  cases o f  suspected CF or 
bronchiectasis of unknown cause.
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